MASH Cities

Episode 6, Season 3 is out... (but not on Netflix) To watch the latest on EASL | The Home of Hepatology policy dialogues, you'll want to tune in below ⤵️ https://lnkd.in/eTCU7Ex5 In this episode🎙️, MASH Cities Chair Jeffrey V. Lazarus and President of the American Association for the Study of Liver Diseases (AASLD) W Ray Kim discuss the critical need for liver disease representation at the upcoming Fourth High-level Meeting of the United Nations General Assembly on the prevention and control of NCDs in 2025. They also cover topics like the World Health Organization newly adopted "best buys" and how it targets risk factors for liver disease 🩺 You won't want to miss out!

According to the NYC Mayor’s Office of Food Policy annual 2022 Food Metrics Annual Report, an estimated 1.2 million (14.6%) New York City residents were food insecure. (source:https://lnkd.in/dGdvksuu) What does that mean for cities like NYC and their residents when we know that food insecurity and socioeconomic status play a major role in liver disease prevalence, severity, outcomes and hepatic risk factors (e.g. unhealthy diets 🍟)? Metabolic dysfunction-associated steatotic liver disease (#MASLD) is now the most common liver disease globally 🌍. #FoodInsecurity is an "upstream" risk factor for MASLD, advanced fibrosis and greater all-cause mortality among those living with liver disease. If we do not intervene on food insecurity at four major levels (environment, policy, community and health care), we cannot ↘️ reduce the burden of liver disease, and consequently, close the gap on social and health inequities. 👇 Read the latest on the current research in the field, the need for implementing proven interventions, and the role #liverspecialists especially can have: https://lnkd.in/e2Sx5K5z

You ask, and you shall receive! 💥 We're proud to share the recording of the first-ever policy event on #MASLD and #MASH, which took place alongside the United Nations General Assembly week on September 23rd. Supported by Barcelona Institute for Global Health (ISGlobal) and programmed by Economist Impact, the event welcomed an exclusive fireside chat with ⤵️ 🇲🇽 David Kershenobich, Secretary of Health of Mexico 🇶🇦 H.E. Hanan Mohamed Al Kuwari, Minister of public health, Ministry of Public Health - Qatar. The video recording also shows the dynamic and insightful discussion with 4 expert panellists, including: 🗣 Jeffrey V. Lazarus, Professor of Global Health, CUNY Graduate School of Public Health and Health Policy 🗣 Johanna Ralston, CEO, World Obesity Federation 🗣 Arun Sanyal, Director, VCU Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, Virginia Commonwealth University School of Medicine 🗣 Christoph Benn, Director for Global Health Diplomacy, Joep Lange Institute Free free to watch, share and repost as we continue raising awareness of MASLD and MASH at a city, national and global level to place MASLD and MASH as priority agenda items at the upcoming World Health Assembly in early 2025 and the 4th High-level Meeting of the United Nations General Assembly on the Prevention and Control of NCDs. 📹 https://lnkd.in/dBh-25FR --- Cindy Serdjebi Fatty Liver Alliance Tess E. B. Echosens Jasmina Cunmulaj Leonor Mendoza Bellgardt Brian Li Han Wong Mário Pessoa Joxel Garcia, MD, MBA NYC Department of Health and Mental Hygiene Assia Bourib Satoshi Ezoe Michael Kessler Stephanie Nolen Matthew D'Uva Johanne Morne Emily Baumgaertner Guilherme Gonçalves Duarte, M.D. Kelly Henning, MD Rhitu Chatterjee Nur Bedeir Alina M. Allen Meena Bansal Jeffrey Mechanick Shikha Bharaktiya Jongoh Kim

A 2022 American Heart Association scientific statement recognized #MASLD as an often overlooked independent risk factor for atherosclerotic cardiovascular disease (CVD) and stated that increased risk of CVD in people living with MASLD is sometimes the result of its association with type 2 #diabetes and abdominal adiposity (source 🔎 https://lnkd.in/dMdw2XpU) What opportunities* are we missing 🤔 when it comes to MASLD/MASH and common risk factors in non-communicable diseases? -- *Taken from the 2024 policy brief by Economist Impact that provides an overview of the current US policy landscape for MASLD and MASH, alongside recommendations for policy-makers (https://lnkd.in/egPBWmKt) #MASHCities

Have you ever considered how #mentalhealth is affected in those living with MASLD (formerly NAFLD)? A 2024 study published in JHEP Reports shed light on the profound impact of stigma and self-blame among patients with MASLD. The research revealed that #stigmatization — whether due to liver disease itself or related factors like obesity—was either strongly associated with impaired quality of life or lower quality of life scores, respectively. Perhaps most strikingly, the greatest disease burden was related to patients’ self-blame 👆 for their liver disease, underscoring the need for #empathy and understanding in patient care. To mark #WorldMentalHealthDay, we're sharing two articles that can build awareness among physicians treating #MASLD and contribute to patients' well-being: 🧠The first is the article mentioned above, which aimed to assess the burden of #liverdisease in patients with MASLD and the relationship between experience of stigma and #HRQL. https://lnkd.in/gKjtHyhP 🧠The second describes the multisociety #Delphiconsensus statement on new fatty liver disease nomenclature, highlighting how the new nomenclature strives to accelerate disease awareness while minimizing stigma associated with the use of terms perceived as stigmatising by some patients and their caregivers. https://lnkd.in/gKjtHyhP

🗓️ October is Liver Cancer Awareness Month, and MASH Cities chair Jeffrey V. Lazarusis calling for urgent action! With MASH becoming a major cause of #livercancer, now is the time 🕐 for policymakers, health organizations, and communities to step up. 🏙️ City health plans, like #HealthyNYC, are clearcut opportunities to integrate MASLD and #MASH alongside other non-communicable diseases and raise the likelihood of better health outcomes across the board. Read the latest US policy brief from Economist Impact about how to turn the tide on MASLD and MASH, today 👉 https://lnkd.in/egPBWmKt #LiverCancerAwarenessMonth #MASHCities #PublicHealth #MASLD #LiverHealth Nina Agrawal Icahn School of Medicine at Mount Sinai NYC Health + Hospitals Fund for Public Health in NYC UChicago Medicine Fatty Liver Alliance Empire Liver Foundation (ELF) American Liver Foundation American Cancer Society International Liver Cancer Movement American Association for the Study of Liver Diseases (AASLD) Arun Sanyal Bloomberg Philanthropies Arizona Liver Health Rohit Kohli, MBBS, MS Tony Villiotti NASH kNOWledge Tom Frieden Scott Isaacs, MD, FACP, FACE Scott C. Ratzan MD Dr. Ashwin Vasan Shyam Bishen, Ph.D., MS, MBA Vanessa Garcia Larsen Anthony Armenta Andrew Sollinger Naveen Rao Michelle Morse

📝 New Policy Insights on MASLD/MASH in the US 📝 The Economist Impact just released a critical policy brief outlining the current landscape for addressing metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe form, MASH, in the US. This chronic liver disease, which can progress to #cirrhosis and #livercancer, requires urgent attention from policy-makers to improve outcomes. Key areas for US policymakers include:  🔬 Enhancing access to diagnostics  📋 Introducing targeted screening for high-risk populations  🩺 Integrating MASLD/MASH into non-communicable disease (NCD) strategies by leveraging common risk factors like obesity and diabetes Let's continue pushing for comprehensive policy changes that will improve prevention, early detection, and treatment of MASLD/MASH - and end the MASLD/MASH public health threat. Full brief here 👇 https://lnkd.in/egPBWmKt #LiverHealth #MASLD #MASH #NCDs #HealthcarePolicy #PublicHealth  #UNGA2024

🚨 The global conversation on liver health is gaining momentum, but there's so much more to be done! This recent piece from The New York Times (https://lnkd.in/gvxJdggi) is a breakthrough in raising awareness of metabolic dysfunction-associated steatotic liver disease (MASLD), formerly called NAFLD. It follows on the recent United Nations General Assembly  #UNGA2024 MASLD/MASH policy side-event, which also aimed to build visibility around the issue and promote the country-specific policy briefs ✍ published by the Economist Impact (https://lnkd.in/dXEAxMdk) Thank you The New York Times for featuring some of the key leaders in the field, including the #NYCMASH Cities co-chair Meena Bansal and Maru/Mary Rinella, who is participating in the #MASHCities 4-city awareness study on MASLD/MASH among the general population, people living with #diabetes and primary care professionals. We note that while New York City has a great #HealthyNYC plan to improve health outcomes, MASLD and MASH are not mentioned at all. 🙋♂️ 🙋♀️ We ask the NYC Department of Health and Mental Hygiene of Health and Mental Hygiene to fix this. All of these actions, from newspaper articles, to citywide and national action plans and strategies will prove vital as we push forward to end the MASLD/MASH #publichealth threat by raising awareness, driving policy changes, and improving health outcomes ↗️ Jeffrey V. Lazarus Nina Agrawal Icahn School of Medicine at Mount Sinai Joxel Garcia, MD, MBA NYC Health + Hospitals Fund for Public Health in NYC UChicago Medicine Fatty Liver Alliance Empire Liver Foundation (ELF) American Liver Foundation American Association for the Study of Liver Diseases (AASLD) Arun Sanyal Bloomberg Philanthropies Arizona Liver Health Rohit Kohli, MBBS, MS Tony Villiotti NASH kNOWledge Tom Frieden James McDonald MD MPH Scott Isaacs, MD, FACP, FACE Scott C. Ratzan MD Pam B. Dr. Ashwin Vasan Shyam Bishen, Ph.D., MS, MBA Vanessa Kerry, MD MSc Jay Bhatt Anthony Armenta Andrew Sollinger Naveen Rao Lars Hartenstein Kate Midden

Yesterday evening, at Icahn School of Medicine at Mount Sinai, MASH Cities Chair Jeffrey V. Lazarus and Co-chair Meena Bansal shared an overview (and their insights💡) of the morning Economist Impact policy side-event on #MASLD and #MASH. The audience was filled with #hepatologists, #patientadvocates and others who were curious 🤔 to learn more about what the keynote speakers and panellists discussed in terms of taking action to address these chronic liver diseases. As Dr. Meena Bansal reiterated from the #UNGA2024 side-event discussions⤵ "... That evidence, economics and emotion ... we need to translate that and get that to the policymakers, to the providers and and to the patients." Finally, to close up the evening reception, we heard some stories from patients and advocates including the American Liver Foundation who reminded everyone of why it is so important to continue involving and listening to the patient's voice as we move forward in this initiative🗣 Thank you for all those who attended, and we look forward to our next #NYCMASH gathering in the Big 🍎 !

💬“We need more studies. We need more data. But the data we have is enough to take action!"💬 -H.E. Hanan Mohamed Al Kuwari, Minister of Public Health (Ministry of Public Health - Qatar) That statement was one of the key messages to be delivered during today's first-ever Economist Impact side-event on #MASLD and #MASH during the United Nations General Assembly week. But, it definitely wasn't the last and only ⬇ The event welcomed insightful conversations and comments from other expert leaders on the #publichealth threat, including: 🗣David Kershenobich, director general, National Institute of Medical Sciences and Nutrition Salvador Zubirán 🗣Jeffrey V. Lazarus, Professor of Global Health, CUNY Graduate School of Public Health and Health Policy 🗣 Johanna Ralston, CEO, World Obesity Federation 🗣 Arun Sanyal, Director, VCU Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, Virginia Commonwealth University School of Medicine 🗣 Christoph Benn, Director for Global Health Diplomacy, Joep Lange Institute We also heard Q&A 🖐 from a diverse audience (65+ attendees) that included academia & education, government, NGO & local authorities, healthcare and pharmaceuticals. Finally, in our post-event networking session, participants and speakers had the opportunity to get a more real-world understanding of #liverfibrosis with a demo session by Echosens and their non-invasive ultrasound technology. -- Later this week, MASH Cities will share the full recording 📹 and a more comprehensive overview of the take-aways messages from all of our speakers and participants. Make sure to stay tuned! And in the meanwhile, read up on the 3 latest country-specific policy briefs (US, Japan, and Germany) prepared in collaboration with the Economist Impact ✍ https://lnkd.in/dXEAxMdk -- The event is supported financially by Novo Nordisk, Echosens, CUNY Graduate School of Public Health and Health Policy and the CUNY SPH Foundation. #UNGA2024 #liverdisease #communityofpractice #globalaction